Ubs Group Ag Neu Base Therapeutics, Inc. Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.17 - $0.39 $632 - $1,451	3,723 New	3,723 $0
Q2 2022 Aug 10, 2022	BUY	$0.82 - $1.93 $2,014 - $4,742	2,457 New	2,457 $3,000
Q1 2022 May 16, 2022	SELL	$1.26 - $2.95 $9,369 - $21,936	-7,436 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.6 - $4.18 $5,860 - $9,421	2,254 Added 43.5%	7,436 $21,000
Q3 2021 Nov 15, 2021	BUY	$3.27 - $4.76 $16,569 - $24,118	5,067 Added 4406.09%	5,182 $19,000
Q2 2021 Aug 13, 2021	SELL	$4.63 - $7.34 $13,028 - $20,654	-2,814 Reduced 96.07%	115 $1,000
Q1 2021 May 12, 2021	BUY	$6.92 - $12.36 $809 - $1,446	117 Added 4.16%	2,929 $22,000
Q4 2020 Feb 11, 2021	BUY	$6.92 - $9.25 $9,362 - $12,515	1,353 Added 92.73%	2,812 $19,000
Q3 2020 Nov 12, 2020	SELL	$7.25 - $9.71 $30,341 - $40,636	-4,185 Reduced 74.15%	1,459 $11,000
Q2 2020 Jul 31, 2020	BUY	$6.69 - $11.51 $36,821 - $63,351	5,504 Added 3931.43%	5,644 $49,000
Q1 2020 May 01, 2020	SELL	$4.77 - $8.23 $982 - $1,695	-206 Reduced 59.54%	140 $1,000
Q4 2019 Feb 14, 2020	SELL	$4.5 - $8.1 $15,295 - $27,531	-3,399 Reduced 90.76%	346 $2,000
Q3 2019 Nov 14, 2019	BUY	$3.15 - $6.59 $11,796 - $24,679	3,745 New	3,745 $19,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.